Compare ACADIA Pharmaceuticals Inc. (ACAD) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs KraneShares CSI China Internet ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.79 (market cap $4.49B), while KraneShares CSI China Internet ETF trades at $26.45. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | KWEB | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Sector/Thematic |
52-Week High | $28.06 | $42.94 |
52-Week Low | $20.06 | $23.63 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
KWEB, the KraneShares CSI China Internet ETF, trades at $25.59, up 2.44% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF offers concentrated exposure to Chinese internet and AI companies, currently near 52-week lows, benefiting from AI-driven growth and government support. Recent news highlights China's factory rebound and substantial AI infrastructure investments.
The outlook for KWEB is mixed; attractive valuations and AI tailwinds present opportunities, but risks include US-China tensions and China's economic volatility. Analyst sentiment is cautious due to geopolitical and regulatory uncertainties, though long-term growth potential in Chinese tech remains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
